1. A method for rapid and reliable quantification of VEGF-cell binding activity.
- Author
-
Waduge P, Kaur A, and Li W
- Subjects
- Humans, HEK293 Cells, Protein Isoforms metabolism, Receptors, Vascular Endothelial Growth Factor metabolism, Bacteriophage T7 metabolism, Bacteriophage T7 genetics, Cell Surface Display Techniques methods, Heparitin Sulfate metabolism, Recombinant Fusion Proteins, Vascular Endothelial Growth Factor A metabolism, Human Umbilical Vein Endothelial Cells metabolism, Protein Binding
- Abstract
Vascular endothelial growth factor (VEGF) is a pleiotropic growth factor that binds a broad spectrum of cell types and regulates diverse cellular processes, including angiogenesis, growth and survival. However, it is technically difficult to quantify VEGF-cell binding activity because of reversible nature of ligand-receptor interactions. Here we used T7 bacteriophage display to quantify and compare binding activity of three human VEGF-A (hVEGF) isoforms, including hVEGF111, 165 and 206. All three isoforms bound equally well to immobilized aflibercept, a decoy VEGF receptor. hVEGF111-Phage exhibited minimal binding to immobilized heparan sulfate, whereas hVEGF206-Phage and hVEGF165-Phage had the highest and intermediate binding to heparan, respectively. In vitro studies revealed that all three isoforms bound to human umbilical vein endothelial cells (HUVECs), HEK293 epithelial and SK-N-AS neuronal cells. hVEGF111-Phage has the lowest binding activity, while hVEGF206-Phage has the highest binding. hVEGF206-Phage was the most sensitive to detect VEGF-cell binding, albeit with the highest background binding to SK-N-AS cells. These results suggest that hVEGF206-Phage is the best-suited isoform to quantify VEGF-cell binding even though VEGF165 is the most biologically active. Furthermore, this study demonstrates the utility of T7 phage display as a platform for rapid and convenient ligand-cell binding quantification with pros and cons discussed., Competing Interests: Declaration of competing interest W. Li is shareholders of Everglades Biopharma, LLC and LigandomicsRx, LLC. W. Li is an inventor of issued and pending patents. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF